PURPOSE: Less than 5% of patients with cancer participate in trials. Few studies have specifically addressed the role of cost to the patient as an influence on trial participation. Our main purpose was to determine the importance of added cost as a barrier to clinical trial participation in the community setting. Our secondary goal was to determine the most prevalent barriers to trial participation for patients. PATIENTS AND METHODS: Four community practices in New England issued surveys to consecutive cohorts of patients with cancer. Patients were assessed for eligibility for clinical trials at their practice site. Trial-eligible patients who declined participation were asked to select reasons that contributed to their decision. RESULTS: Surveys were issued to 1,755 patients. Seventy-one percent of all trial-eligible patients returned surveys. Forty-four percent of nonparticipating trial-eligible patients did not recall hearing about clinical trials from their provider. The most common reasons cited by trial-eligible patients for declining trial participation were fear of adverse effects (50%) and discomfort with random assignment (44%). Twenty-eight percent cited concerns about added cost, and 12% noted cost as the most important factor in their decision. CONCLUSION: Concerns about adverse effects and random assignment were the most common reasons cited by patients declining trial participation in four community oncology practices in New England. Cost considerations were important for a significant proportion of these patients. Many patients eligible for trial participation were not informed by their provider about the availability of research trials.
PURPOSE: Less than 5% of patients with cancer participate in trials. Few studies have specifically addressed the role of cost to the patient as an influence on trial participation. Our main purpose was to determine the importance of added cost as a barrier to clinical trial participation in the community setting. Our secondary goal was to determine the most prevalent barriers to trial participation for patients. PATIENTS AND METHODS: Four community practices in New England issued surveys to consecutive cohorts of patients with cancer. Patients were assessed for eligibility for clinical trials at their practice site. Trial-eligible patients who declined participation were asked to select reasons that contributed to their decision. RESULTS: Surveys were issued to 1,755 patients. Seventy-one percent of all trial-eligible patients returned surveys. Forty-four percent of nonparticipating trial-eligible patients did not recall hearing about clinical trials from their provider. The most common reasons cited by trial-eligible patients for declining trial participation were fear of adverse effects (50%) and discomfort with random assignment (44%). Twenty-eight percent cited concerns about added cost, and 12% noted cost as the most important factor in their decision. CONCLUSION: Concerns about adverse effects and random assignment were the most common reasons cited by patients declining trial participation in four community oncology practices in New England. Cost considerations were important for a significant proportion of these patients. Many patients eligible for trial participation were not informed by their provider about the availability of research trials.
Authors: Carol P Somkin; Andrea Altschuler; Lynn Ackerson; Ann M Geiger; Sarah M Greene; Judy Mouchawar; Joan Holup; Louis Fehrenbacher; Andrew Nelson; Andrew Glass; Jonathan Polikoff; Sigrid Tishler; Carolyn Schmidt; Terry Field; Edward Wagner Journal: Am J Manag Care Date: 2005-07 Impact factor: 2.229
Authors: Ronald S Go; Kathleen A Frisby; Jennifer A Lee; Michelle A Mathiason; Christine M Meyer; Jodi L Ostern; Sara M Walther; Jonean E Schroeder; Lori A Meyer; Kathryn E Umberger Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Neal J Meropol; Joanne S Buzaglo; Jennifer Millard; Nevena Damjanov; Suzanne M Miller; Caroline Ridgway; Eric A Ross; John D Sprandio; Perry Watts Journal: J Natl Compr Canc Netw Date: 2007-09 Impact factor: 11.908
Authors: Ari Umutyan; Christine Chiechi; Laurel A Beckett; Debora A Paterniti; Corinne Turrell; David R Gandara; Sharon W Davis; Ted Wun; Moon S Chen; Primo N Lara Journal: Cancer Date: 2008-01-01 Impact factor: 6.860
Authors: Surbhi Sidana; Cristine Allmer; Melissa C Larson; Amylou Dueck; Kathleen Yost; Rahma Warsame; Gita Thanarajasingam; James R Cerhan; Jonas Paludo; S Vincent Rajkumar; Thomas M Habermann; Grzegorz S Nowakowski; Yi Lin; Morie A Gertz; Thomas Witzig; Angela Dispenzieri; Wilson I Gonsalves; Stephen M Ansell; Carrie A Thompson; Shaji K Kumar Journal: JCO Oncol Pract Date: 2022-05-17
Authors: Lauren M Hamel; David W Dougherty; Seongho Kim; Elisabeth I Heath; Lorna Mabunda; Eyouab Tadesse; RaeAnn Hill; Susan Eggly Journal: Trials Date: 2021-09-17 Impact factor: 2.728
Authors: Diane St Germain; Andrea M Denicoff; Eileen P Dimond; Angela Carrigan; Rebecca A Enos; Maria M Gonzalez; Kathy Wilkinson; Michelle A Mathiason; Brenda Duggan; Shaun Einolf; Worta McCaskill-Stevens; Donna M Bryant; Michael A Thompson; Stephen S Grubbs; Ronald S Go Journal: J Oncol Pract Date: 2014-01-14 Impact factor: 3.840
Authors: Bradley S Peterson; Amy E West; John R Weisz; Wendy J Mack; Michele D Kipke; Robert L Findling; Brian S Mittman; Ravi Bansal; Steven Piantadosi; Glenn Takata; Corinna Koebnick; Ceth Ashen; Christopher Snowdy; Marie Poulsen; Bhavana Kumar Arora; Courtney M Allem; Marisa Perez; Stephanie N Marcy; Bradley O Hudson; Stephanie H Chan; Robin Weersing Journal: BMC Psychiatry Date: 2021-06-30 Impact factor: 3.630
Authors: Andrea M Denicoff; Worta McCaskill-Stevens; Stephen S Grubbs; Suanna S Bruinooge; Robert L Comis; Peggy Devine; David M Dilts; Michelle E Duff; Jean G Ford; Steven Joffe; Lidia Schapira; Kevin P Weinfurt; Margo Michaels; Derek Raghavan; Ellen S Richmond; Robin Zon; Terrance L Albrecht; Michael A Bookman; Afshin Dowlati; Rebecca A Enos; Mona N Fouad; Marjorie Good; William J Hicks; Patrick J Loehrer; Alan P Lyss; Steven N Wolff; Debra M Wujcik; Neal J Meropol Journal: J Oncol Pract Date: 2013-10-15 Impact factor: 3.840
Authors: Grace Clarke Hillyer; Sarah A MacLean; Melissa Beauchemin; Corey H Basch; Karen M Schmitt; Leslie Segall; Moshe Kelsen; Frances L Brogan; Gary K Schwartz Journal: JMIR Cancer Date: 2018-06-26